Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Tagrisso Reimbursed In Korea, After Difficult Price Negotiations

Executive Summary

Korea's National Health Insurance Service and AstraZeneca reach an agreement on reimbursement of Tagrisso, sharply reducing financial burdens of NSCLC patients in the country. Tough price negotiations between the two sides underlines the difficulties pricey innovative drugs face to get reimbursed in the country.

Advertisement

Related Content

Hanmi Halts Olmutinib Development After Alliances Crumble
Hanmi Mulls New Trial Strategy As ZAI Lab Ends Olmutinib Partnership
Korea Signals Continued Policy Support For Pharma In 2018
Korea Takes Its First Step Reimbursing IO Drugs
Korea's Reimbursement Steps Spark Drug Price Cut Concerns
Korean Tagrisso Launch Builds On Extensive Local Data

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS122145

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel